Sec Form 13G Filing - Syncona Portfolio Ltd @ Freeline Therapeutics Holdings plc

Sec Form 13G Filing - Syncona Portfolio Ltd filing for Freeline Therapeutics Holdings plc (FRLN) - 2021-02-12

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Freeline Therapeutics Holdings plc

(Name of Issuer)

American Depositary Shares and Ordinary Shares, nominal value £0.0001 per share

(Title of Class of Securities)

35655L 107**

(CUSIP Number)

December 31, 2020

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☐

Rule 13d-1(c)

☒

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

There is no CUSIP number assigned to the ordinary shares. CUSIP number 35655L 107 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “FRLN.” Each American Depositary Share represents the right to receive one ordinary share.

SCHEDULE 13G/A

CUSIP No. 35655L 107

(1)

Consists of 15,864,527 ordinary shares and 2,950,000 American Depositary Shares (“ADSs”) held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.0001 per share, of the Issuer. The ordinary shares and the ADS are collectively referred to as the “Ordinary Shares”.

(2)

Based on 34,744,687 Ordinary Shares outstanding after the Issuer’s initial public offering (the “IPO”), which includes all outstanding ADSs on an as-converted basis, assuming no exercise of the underwriters’ option in connection with the IPO, as reported in the prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (the “SEC”) on August 10, 2020.

Page 2 of 8

SCHEDULE 13G

CUSIP No. 35655L 107

(1)	Consists of 15,864,527 ordinary shares and 2,950,000 ADS held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.0001 per share, of the Issuer.

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned by Syncona Portfolio Limited is set forth on Line 11 above. Based on 34,744,687 Ordinary Shares outstanding after the Issuer’s IPO, which includes all outstanding ADSs on an as-converted basis, assuming no exercise of the underwriters’ option in connection with the IPO, as reported in the prospectus filed pursuant to Rule 424(b)(4) with the SEC on August 10, 2020.

Page 3 of 8

SCHEDULE 13G

CUSIP No. 35655L 107

(1)	Consists of 15,864,527 ordinary shares and 2,950,000 ADS held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.0001 per share, of the Issuer.

(2)

Page 4 of 8

SCHEDULE 13G

CUSIP No. 35655L 107

(1)	Consists of 15,864,527 ordinary shares and 2,950,000 ADS held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.0001 per share, of the Issuer.

(2)

Page 5 of 8

Item 1.

(a) Name of Issuer: Freeline Therapeutics Holdings plc

(b) Address of Issuer’s principal executive offices: Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom

Item 2.

(a)

Name of reporting persons filing:

(i)

Syncona Portfolio Limited;

(ii)

Syncona Holdings Limited;

(iii)

Syncona Investment Management Limited; and

(iv)

Syncona Limited

(b)

Address of principal business office or, if none, residence:

The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Synocna Limited is Arnold House, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.

(c)

Citizenship:

Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited’s citizenship is United Kingdom.

(d)

Title and class of securities:

Ordinary Shares, nominal value £0.0001 per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value £0.0001 per share, of the Issuer.

(e)

CUSIP No.:

There is no CUSIP number assigned to the ordinary shares. CUSIP number 35655L 107 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “FRLN.”

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Page 6 of 8

Item 4.

The following information with respect to the ownership of Ordinary Shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020:


Reporting Persons	Ordinary Shares Held Directly (1)		Sole Power to Vote or Direct the Vote (1)		Shared Power to Vote or Direct the Vote (1)		Sole Power to Dispose or Direct the Disposition (1)		Shared Power to Dispose or Direct the Disposition (1)		Amount Beneficially Owned (1)		Percentage of Class (2)
Syncona Portfolio Limited		0		0		18,814,527		0		18,814,527		18,814,527		54.2	%
Syncona Holdings Limited		18,814,527		0		18,814,527		0		18,814,527		18,814,527		54.2	%
Syncona Investment Management Limited		0		0		18,814,527		0		18,814,527		18,814,527		54.2	%
Syncona Limited		0		0		18,814,527		0		18,814,527		18,814,527		54.2	%

(1)

(2)

The percentage of outstanding Ordinary Shares of the Issuer beneficially owned was calculated based on 34,744,687 Ordinary Shares outstanding after the Issuer’s initial public offering (the “IPO”), which includes all outstanding ADSs on an as-converted basis, assuming no exercise of the underwriters’ option in connection with the IPO, as reported in the prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on August 10, 2020.

The shares are owned directly by Syncona Portfolio Limited (“Syncona Portfolio”) and indirectly by Syncona Holdings Limited (“Syncona Holdings”) and Syncona Limited (“Syncona Limited”). Syncona Portfolio is a wholly owned subsidiary of Syncona Holdings, and Syncona Holdings is a wholly controlled subsidiary of Syncona Limited (“Syncona Limited”), a publicly-listed company. Investment and voting decisions with respect to these shares are made by Syncona Portfolio, acting upon the recommendation of an investment committee of Syncona Investment Management Limited, also a subsidiary of Syncona Holdings. Each of these entities disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Not applicable.

Item 8.

Identification and classification of members of the group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

Page 7 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2021


SYNCONA PORTFOLIO LIMITED

By:		/s/ Robert Hutchinson
Name:		Robert Hutchinson
Title:		Director

SYNCONA HOLDINGS LIMITED

By:		/s/ Robert Hutchinson
Name:		Robert Hutchinson
Title:		Director

SYNCONA INVESTMENT MANAGEMENT LIMITED

By:		/s/ John Bradshaw
Name:		John Bradshaw
Title:		CFO

SYNCONA LIMITED

By:		/s/ Robert Hutchinson
Name:		Robert Hutchinson
Title:		Director

Exhibit(s):


Exhibit 99.1:		Joint Filing Statement

Page 8 of 8

Names of Reporting Person:

Syncona Portfolio Limited

Check the appropriate box if a member of a Group (see instructions)

(a) ☐ (b) ☒

SEC Use Only

Citizenship or Place of Organization

Guernsey